Filana Therapeutics, Inc. Finite-Lived Intangible Asset, Expected Amortization, Year One
Filana Therapeutics, Inc. (FLNA) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $45.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-03-12
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $45.00K.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $17.00K.
- 2024-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $18.00K.
- 2024-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $11.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2025-12-31 | $45.00K 10-K · filed 2026-03-12 |
| 2024-12-31 | $17.00K 10-K · filed 2025-03-03 |
| 2024-09-30 | $18.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $11.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $4.00K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $172.00K 10-K · filed 2024-02-28 |
| 2023-09-30 | $167.00K 10-Q · filed 2023-11-07 |
| 2023-06-30 | $167.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $167.00K 10-Q · filed 2023-05-01 |
| 2022-12-31 | $451.00K 10-K · filed 2023-02-28 |
| 2022-09-30 | $444.00K 10-Q · filed 2022-11-07 |
| 2022-06-30 | $444.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $431.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $464.00K 10-K · filed 2022-03-01 |
| 2021-09-30 | $464.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |